Printer Friendly

MDA allocates USD12m for neuromuscular disease research.

M2 PHARMA-February 2, 2012-MDA allocates USD12m for neuromuscular disease research(C)2012 M2 COMMUNICATIONS

2 February 2012 - The Muscular Dystrophy Association allocated over USD12m (EUR9.1m) to fund 38 research projects focused on the causes and potential treatments for various forms of neuromuscular disease.

The new grants, which became available as of 1 February 2012, will be used to fund research into over 15 diseases in MDA's program, including Duchenne muscular dystrophy (DMD), ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease), spinal muscular atrophy (SMA), facioscapulohumeral muscular dystrophy (FSHD), among others.

Apart from supporting research into the disease mechanisms, the grants will also help progress the development of strategies for diagnosis and treatment.

(USD1 = EUR0.759)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 2, 2012
Words:127
Previous Article:Vascular Solutions offers reprocessing service for ClosureFAST catheters.
Next Article:EUSA Pharma secures rights to ASPAREC from Alize Pharma.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters